Occurrence of Radiation-induced Otitis Media in Nasopharyngeal Carcinoma Patients After Intensity Modulated Radiotherapy

This is an observational cohort study to investigate the incidence of radiation-induced otitis media, changes in tubal function and hearing in newly diagnosed nasopharyngeal carcinoma patients without metastasis at multiple time points from baseline to 1 year after radiotherapy.

Sex

All

Minimum age

18 Years

Maximum age

70 Years

Inclusion Criteria:

* Age 18-70, regardless of sex.
* ECOG (Eastern Cooperative Oncology Group) score: 0-1.
* Patients must sign informed consent and be willing, and well understood the objective and procedure of this study.
* Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma, type of WHO II or III, clinical stage I-IVa (according to the 8th American Joint Committee on Cancer \[AJCC\] edition.
* No radiotherapy or chemotherapy was administered before enrollment.
* Expected survival time ≥ 6 months.

Exclusion Criteria:

* Women in pregnancy or lactation.
* Patients with significantly lower heart, liver, lung, kidney, bone marrow function and other severe medical condition.
* Prior to radiotherapy, there is a clear underlying disease of the eustachian tube or other ear diseases.
* Patients with otitis media before radiotherapy and have no improvement at the end of radiotherapy.
* Patients with history of middle ear, nasal or nasopharyngeal surgery on the affected side.
* Patients combined with congenital cleft palate and other craniofacial abnormalities.
* Patients with histologically confirmed keratinizing nasopharyngeal carcinoma, type of WHO I.
* Patients with recurrence and distant metastasis.
* Patients with radiotherapy or chemotherapy before.
* Age \< 18 or age \> 70.
* Patients who changed their initial treatment regimen during the observation period due to disease progression (including tumor residual after radiotherapy, tumor recurrence, and new distant metastases).

• BACKGROUNDChen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019 Jul 6;394(10192):64-80. doi: 10.1016/S0140-6736(19)30956-0. Epub 2019 Jun 6. PMID 31178151
• BACKGROUNDEmami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22. doi: 10.1016/0360-3016(91)90171-y. PMID 2032882
• BACKGROUNDHsin CH, Tseng HC, Lin HP, Chen TH. Post-irradiation otitis media, rhinosinusitis, and their interrelationship in nasopharyngeal carcinoma patients treated by IMRT. Eur Arch Otorhinolaryngol. 2016 Feb;273(2):471-7. doi: 10.1007/s00405-015-3518-8. Epub 2015 Jan 30. PMID 25634060
• BACKGROUNDHsin CH, Chen TH, Liang KL, Tseng HC, Liu WS. Postirradiation otitis media with effusion in nasopharyngeal carcinoma patients treated by intensity-modulated radiotherapy. Laryngoscope. 2013 Sep;123(9):2148-53. doi: 10.1002/lary.23215. Epub 2013 Jul 8. PMID 23835775
• BACKGROUNDYao JJ, Zhou GQ, Lin L, Zhang WJ, Peng YL, Chen L, Tang LL, Mao YP, Ma J, Sun Y. Dose-volume factors associated with ear disorders following intensity modulated radiotherapy in nasopharyngeal carcinoma. Sci Rep. 2015 Sep 1;5:13525. doi: 10.1038/srep13525. PMID 26323586
• BACKGROUNDWang SZ, Wang WF, Zhang HY, Guo M, Hoffman MR, Jiang JJ. Analysis of anatomical factors controlling the morbidity of radiation-induced otitis media with effusion. Radiother Oncol. 2007 Dec;85(3):463-8. doi: 10.1016/j.radonc.2007.10.007. Epub 2007 Nov 19. PMID 18006095